This trial is looking at whether adding oral anticoagulation to background antiplatelet therapy is effective and safe in preventing thromboembolic events in patients who develop new-onset atrial fibrillation after isolated coronary artery bypass graft surgery.
2 Primary · 10 Secondary · Reporting Duration: 90 days after randomization
3200 Total Participants · 2 Treatment Groups
Primary Treatment: Antiplatelet Therapy · No Placebo Group · Phase 4
Age 18+ · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: